RxDoctor Payments DataLook up a doctor →

Constantine Demetracopoulos, MD

Foot and Ankle Surgery · New York, NYNPI 1346417805

Payments from drug & device makers

$888,116in general payments, 2019–2025

Across 630 payments — averaging $1409.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exactech, Inc.$606K
  • Arthrex$167K
  • Stryker$23K
  • Treace Medical Concepts, Inc.$15K
  • Responsive Arthroscopy Inc$14K
  • Medshape, Inc.$12K
  • plus $51K from 18 others
$250in research payments, 2019–2025

Across 1 payment — averaging $250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Integra Lifesciences Corporation$250

What the payments were for

  • Royalty or licence$39,3844%
  • Consulting fees$661,12574%
  • Speaking & faculty fees$89,47510%
  • Grants$8,5081%
  • Travel & lodging$73,3858%
  • Food & beverage$16,2392%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$888,116 in reported general payments places this provider in the 95th percentile of 652 foot and ankle surgery providers in New York.

See all foot and ankle surgery providers in New York

Medicare billing

Part B allowed, 2024
$143,448
Medicare patients
351
Services billed
673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib12$737
Meloxicam19$55

Paid to pharmacies, not to this prescriber.

Other foot and ankle surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →